ProShares UltraShort NASDAQ Biotechnology
8 hedge funds and large institutions have $7.11M invested in ProShares UltraShort NASDAQ Biotechnology in 2018 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 5 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
27% more capital invested
Capital invested by funds: $5.61M → $7.11M (+$1.49M)
20% more call options, than puts
Call options by funds: $559K | Put options by funds: $467K
2.14% more ownership
Funds ownership: 20.06% → 22.19% (+2.1%)
27% less funds holding
Funds holding: 11 → 8 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$486K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$412K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$54.8K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$18.9K |
| 5 |
Morgan Stanley
New York
|
+$161 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
WealthSource Partners
San Luis Obispo,
California
|
-$1.05M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$670K |
| 3 |
VF
Virtu Financial
New York
|
-$545K |
| 4 |
Citigroup
New York
|
-$22.1K |
| 5 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$22K |
BIS Hedge Fund Activity: Q4 2018 in Review
8 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q4 2018, worth a combined $7.11M — up 27% from $5.61M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of BIS and 2 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 4 added.
The largest buyer was Jane Street, adding an estimated $486K. The largest seller was WealthSource Partners, exiting entirely with an estimated $1.05M sold.
- 8 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q4 2018, down from 11 in Q3 2018.
- Funds reported $7.11M of ProShares UltraShort NASDAQ Biotechnology stock for Q4 2018, up 27% quarter-over-quarter.
- 2 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q4 2018 and 5 closed out, a net change of -3 holders.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q4 2018 was Jane Street, an estimated $486K added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q4 2018 was WealthSource Partners, an estimated $1.05M sold.
Based on aggregated 13F filings for Q4 2018.